Cutting edge

Inhibiting TBK1 by compound II ameliorates autoimmune disease in mice

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

TANK-binding kinase 1 (TBK1) is a serine/threonine protein kinase that plays a crucial role in innate immunity. Enhanced TBK1 function is associated with autoimmune diseases and cancer, implicating the potential benefit of therapeutically targeting TBK1. In this article, we examined a recently identified TBK1 inhibitor Compound II on treating autoimmune diseases. We found that Compound II is a potent and specific inhibitor of TBK1-mediated IFN response. Compound II inhibited polyinosinic-polycytidylic acid-induced immune activation in vitro and in vivo. Compound II treatment also ameliorated autoimmune disease phenotypes of Trex1-/- mice, increased mouse survival, and dampened the IFN gene signature in TREX1 mutant patient lymphoblasts. In addition, we found that TBK1 gene expression is elevated in systemic lupus erythematosus patient cells, and systemic lupus erythematosus cells with high IFN signature responded well to Compound II treatment. Together, our findings provided critical experimental evidence for inhibiting TBK1 with Compound II as an effective treatment for TREX1-associated autoimmune diseases and potentially other interferonopathies.

Original languageEnglish (US)
Pages (from-to)4573-4577
Number of pages5
JournalJournal of Immunology
Volume195
Issue number10
DOIs
StatePublished - Nov 15 2015

Fingerprint

Autoimmune Diseases
Phosphotransferases
Systemic Lupus Erythematosus
Poly I-C
Protein-Serine-Threonine Kinases
Innate Immunity
Therapeutics
Phenotype
Gene Expression
Genes
Neoplasms

ASJC Scopus subject areas

  • Immunology

Cite this

Cutting edge : Inhibiting TBK1 by compound II ameliorates autoimmune disease in mice. / Hasan, Maroof; Dobbs, Nicole; Khan, Shaheen; White, Michael A.; Wakeland, Edward K.; Li, Quan Zhen; Yan, Nan.

In: Journal of Immunology, Vol. 195, No. 10, 15.11.2015, p. 4573-4577.

Research output: Contribution to journalArticle

@article{9b9dc054efb14f0a8a52caa954a4b74d,
title = "Cutting edge: Inhibiting TBK1 by compound II ameliorates autoimmune disease in mice",
abstract = "TANK-binding kinase 1 (TBK1) is a serine/threonine protein kinase that plays a crucial role in innate immunity. Enhanced TBK1 function is associated with autoimmune diseases and cancer, implicating the potential benefit of therapeutically targeting TBK1. In this article, we examined a recently identified TBK1 inhibitor Compound II on treating autoimmune diseases. We found that Compound II is a potent and specific inhibitor of TBK1-mediated IFN response. Compound II inhibited polyinosinic-polycytidylic acid-induced immune activation in vitro and in vivo. Compound II treatment also ameliorated autoimmune disease phenotypes of Trex1-/- mice, increased mouse survival, and dampened the IFN gene signature in TREX1 mutant patient lymphoblasts. In addition, we found that TBK1 gene expression is elevated in systemic lupus erythematosus patient cells, and systemic lupus erythematosus cells with high IFN signature responded well to Compound II treatment. Together, our findings provided critical experimental evidence for inhibiting TBK1 with Compound II as an effective treatment for TREX1-associated autoimmune diseases and potentially other interferonopathies.",
author = "Maroof Hasan and Nicole Dobbs and Shaheen Khan and White, {Michael A.} and Wakeland, {Edward K.} and Li, {Quan Zhen} and Nan Yan",
year = "2015",
month = "11",
day = "15",
doi = "10.4049/jimmunol.1500162",
language = "English (US)",
volume = "195",
pages = "4573--4577",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "10",

}

TY - JOUR

T1 - Cutting edge

T2 - Inhibiting TBK1 by compound II ameliorates autoimmune disease in mice

AU - Hasan, Maroof

AU - Dobbs, Nicole

AU - Khan, Shaheen

AU - White, Michael A.

AU - Wakeland, Edward K.

AU - Li, Quan Zhen

AU - Yan, Nan

PY - 2015/11/15

Y1 - 2015/11/15

N2 - TANK-binding kinase 1 (TBK1) is a serine/threonine protein kinase that plays a crucial role in innate immunity. Enhanced TBK1 function is associated with autoimmune diseases and cancer, implicating the potential benefit of therapeutically targeting TBK1. In this article, we examined a recently identified TBK1 inhibitor Compound II on treating autoimmune diseases. We found that Compound II is a potent and specific inhibitor of TBK1-mediated IFN response. Compound II inhibited polyinosinic-polycytidylic acid-induced immune activation in vitro and in vivo. Compound II treatment also ameliorated autoimmune disease phenotypes of Trex1-/- mice, increased mouse survival, and dampened the IFN gene signature in TREX1 mutant patient lymphoblasts. In addition, we found that TBK1 gene expression is elevated in systemic lupus erythematosus patient cells, and systemic lupus erythematosus cells with high IFN signature responded well to Compound II treatment. Together, our findings provided critical experimental evidence for inhibiting TBK1 with Compound II as an effective treatment for TREX1-associated autoimmune diseases and potentially other interferonopathies.

AB - TANK-binding kinase 1 (TBK1) is a serine/threonine protein kinase that plays a crucial role in innate immunity. Enhanced TBK1 function is associated with autoimmune diseases and cancer, implicating the potential benefit of therapeutically targeting TBK1. In this article, we examined a recently identified TBK1 inhibitor Compound II on treating autoimmune diseases. We found that Compound II is a potent and specific inhibitor of TBK1-mediated IFN response. Compound II inhibited polyinosinic-polycytidylic acid-induced immune activation in vitro and in vivo. Compound II treatment also ameliorated autoimmune disease phenotypes of Trex1-/- mice, increased mouse survival, and dampened the IFN gene signature in TREX1 mutant patient lymphoblasts. In addition, we found that TBK1 gene expression is elevated in systemic lupus erythematosus patient cells, and systemic lupus erythematosus cells with high IFN signature responded well to Compound II treatment. Together, our findings provided critical experimental evidence for inhibiting TBK1 with Compound II as an effective treatment for TREX1-associated autoimmune diseases and potentially other interferonopathies.

UR - http://www.scopus.com/inward/record.url?scp=84954132420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954132420&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1500162

DO - 10.4049/jimmunol.1500162

M3 - Article

VL - 195

SP - 4573

EP - 4577

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 10

ER -